SCHEMBL29378128

SCHEMBL29378128

FC(F)(F)c1c[nH]c2ccnc(Cl)c12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.34
DYRK1A Q13627 3/20 0.33
GSK3B P49841 3/20 0.33
NOTUM Q6P988 2/20 0.33
TAAR1 Q96RJ0 1/20 0.31
NOS3 P29474 1/20 0.31
NOS2 P35228 1/20 0.31
PIK3CD O00329 1/20 0.30
IDO1 P14902 1/20 0.30
CDK5 Q00535 2/20 0.30
CDK5R1 Q15078 2/20 0.30
PDPK1 O15530 1/20 0.30
CCNT1 O60563 1/20 0.30
CCNB2 O95067 1/20 0.30
CDK1 P06493 1/20 0.30
HTR1A P08908 1/20 0.30
CCNB1 P14635 1/20 0.30
PRKACA P17612 1/20 0.30
CCNA2 P20248 1/20 0.30
PRKACG P22612 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22502476 1.00 KMO (0.34) KMODYRK1AGSK3BNOTUMTAAR1
SCHEMBL22494883 0.77 GPR84 (0.34) DYRK1ACDK5CDK5R1CCNT1HTR1A
SCHEMBL29844289 0.73 CHEK1 (0.50) DYRK1ACLK1
SCHEMBL30373345 0.73 CDK5 (0.38) GSK3BCDK5CDK5R1CCNT1CCNB2
SCHEMBL16247667 0.73 ATM (0.35) DYRK1ACDK2
SCHEMBL3190125 0.73 CDK5 (0.38) GSK3BCDK5CDK5R1CCNT1CCNB2
SCHEMBL15345660 0.73 CHEK1 (0.50) DYRK1ACLK1
SCHEMBL2692195 0.72 LRRK2 (0.53) KMOGSK3BNOTUMCDK5CDK5R1
SCHEMBL30543151 0.72 LRRK2 (0.53) KMOGSK3BNOTUMCDK5CDK5R1
SCHEMBL15084530 0.71 CDK5 (0.41) DYRK1AGSK3BNOTUMCDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250276-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE MITOKININ, INC. (US) 2025-08-07 US disclosed
EP-4168392-A1 SULFONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-04-26 EP disclosed
CN-115916756-A Sulfone derivative 豪夫迈·罗氏有限公司 2023-04-04 CN disclosed
EP-3947390-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE Mitokinin, Inc. (US) 2022-02-09 EP disclosed
CN-114026093-A Compositions for treating neurodegenerative and mitochondrial diseases and methods of use thereof 麦托吉宁公司 2022-02-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250276-A1 COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE PINK1, NLN, NME4 KMO 624/4885DYRK1A 1797/4885GSK3B 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.